GHK-Cu: Research Overview

The short version

GHK-Cu is a copper tripeptide (Gly-His-Lys chelated to a Cu(II) ion) that occurs naturally in human plasma, declining from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 ^[21]. In cell and animal studies, it stimulates skin fibroblasts to produce collagen, elastin, and glycosaminoglycans, and it appears to modulate a broad gene-expression program favoring tissue repair and antioxidant defense ^[19].

Topical GHK-Cu is a legal cosmetic ingredient in the US and EU with a long safety record. A 6-month RCT in 45 men with androgenetic alopecia found statistically significant hair-count increases with a GHK-containing formulation versus placebo ^[20]. However, injectable or systemic use is unapproved and has no validated human pharmacokinetics. Most foundational research comes from a single investigator and colleagues, limiting independent replication ^[18]. This page covers the published evidence — it does not advise on use.

What it is

GHK-Cu is the Glycyl-L-Histidyl-L-Lysine Copper(II) complex — three amino acids chelated to a divalent copper ion. The copper is coordinated through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and a deprotonated amide nitrogen, leaving the lysine side chain free. The GHK sequence occurs endogenously in the alpha-2(I) chain of type I collagen and in SPARC/osteonectin, which is why it was originally identified as a wound-signaling molecule.

Copper tripeptide-1 (the INCI cosmetic name) and GHK-Cu are the same thing. The free tripeptide GHK without bound copper is a different entity — copper coordination is required for most of the documented bioactivities, including MMP-2 stimulation in cell studies ^[21]. GHK-Cu's poor skin penetration (clogP -2.24) is the central delivery challenge; palmitoylated forms and microneedle pretreatment improve it significantly ^[18].

How it works

GHK-Cu operates at picomolar-to-nanomolar concentrations and acts on multiple cell types:

• Dermal fibroblasts: stimulates synthesis of collagen, elastin, dermatan sulfate, chondroitin sulfate, and the proteoglycan decorin ^[21].
• Keratinocytes: promotes proliferation and stem-cell markers.
• Hair follicle dermal papilla cells: promotes anagen phase and reduces apoptosis.
• Vascular endothelial cells: supports angiogenesis.
• Antioxidant activity: the copper ion enables superoxide-dismutase-like antioxidant function and, when properly chelated, prevents copper from acting as a pro-oxidant ^[21].

A gene-expression analysis reported GHK modulates approximately 31.2% of human genes at a 50%-or-greater change threshold — 59% upregulated, 41% downregulated — including strong stimulation of the ubiquitin-proteasome system (41 genes up, 1 down), DNA-repair programs, and antioxidant gene sets ^[19]. The often-cited "~4,000 genes" figure is an extrapolation from broader thresholds; the 50%-change table covers approximately 2,100 genes ^[19].

What the research shows

Topical skin efficacy (best human evidence): A 2025 review found procollagen synthesis increased in 70% of GHK-Cu-treated subjects versus 50% for vitamin C and 40% for retinoic acid in reviewed clinical trials. The review also quantifies the central delivery problem: native GHK's clogP of -2.24 limits stratum-corneum penetration significantly, while palmitoylation (Pal-GHK, clogP 1.14) and microneedle pretreatment (~134 nmol GHK permeated versus none through intact skin) substantially improve it ^[18].

Hair loss RCT (strongest controlled human efficacy signal): In a 6-month trial of 45 men with androgenetic alopecia (Norwood-Hamilton grades II–V), a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide (ALAVAX) increased hair count by 52.6 (100 mg/mL) and 71.5 (50 mg/mL) versus 9.6 for placebo (p<0.05). No adverse events in any group ^[20].

Skin-penetration quantification (ex vivo): Copper applied as GHK-Cu penetrated ex vivo human skin with a permeability coefficient of 2.43 x 10^-4 cm/h; over 48 hours, 136.2 µg/cm² permeated and 97 µg/cm² was retained as a dermal depot ^[22].

Gene-expression analysis: Connectivity Map analysis reported GHK modulating 31.2% of human genes at >=50% change — upregulating tissue-repair, protein-quality-control, DNA-fidelity, and antioxidant programs ^[19].

Reported effects, cautions, and safety

What people in research-use and skincare communities report (anecdotal, not clinical evidence): The most common reports for topical use are firmer, tighter-feeling skin; softer fine lines and wrinkles; better hydration and plumpness; smoother texture. Less hair shedding and thicker-looking hair with scalp use is frequently reported. A smaller group reports injectable research use with claims of systemic skin or recovery benefits — these are unsupported by any human pharmacokinetic data. The most common adverse reports are skin irritation, redness, or dryness (especially on sensitive skin or at high concentration), occasional breakouts interpreted as "purging," and the "copper uglies" — a rare reported phenomenon where skin looks transiently worse. Mixing with vitamin C or low-pH acids is a widely noted compatibility problem.

Safety cautions from the published literature:

• Injectable/systemic use is unapproved and has no validated human PK basis — the free peptide is rapidly cleared in blood (rodent data) ^[18].
• Copper accumulation is a theoretical concern with prolonged systemic use, though no human copper-toxicity cases attributed to GHK-Cu appear in the peer-reviewed record.
• People with melasma or prone to dark spots may want to exercise caution: copper feeds into melanin synthesis via tyrosinase ^[21].
• Vitamin C, strong acids (AHAs/BHAs), and retinol can destabilize the copper complex or stack up irritation — separate them by time or alternate days.
• Human evidence is predominantly small topical studies; broader anti-aging claims outpace what controlled trials have shown ^[18][21].

Where it fits in the research landscape

GHK-Cu occupies a unique lane on this desk: it has the longest cosmetic safety track record and a statistically significant human RCT signal for hair regrowth ^[20] — but in the narrow world of topical dermatology. The gene-expression data and the mechanistic scope (31.2% of genes, multiple cell types) suggest biology far more expansive than any controlled human evidence currently documents ^[19].

Distinct from every other compound here in that it is already a legal cosmetic ingredient, requires no physician involvement for topical use, and is widely available in serums and creams. The gap between cosmetic evidence and research-peptide community ambitions (injectable, systemic) is substantial.